WO2001026641A3 - Methode destinee au traitement de l'obesite - Google Patents

Methode destinee au traitement de l'obesite Download PDF

Info

Publication number
WO2001026641A3
WO2001026641A3 PCT/US2000/027252 US0027252W WO0126641A3 WO 2001026641 A3 WO2001026641 A3 WO 2001026641A3 US 0027252 W US0027252 W US 0027252W WO 0126641 A3 WO0126641 A3 WO 0126641A3
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
treatment
morpholinol
derivatives
disclosed
Prior art date
Application number
PCT/US2000/027252
Other languages
English (en)
Other versions
WO2001026641A2 (fr
Inventor
Jessica E Matthews
David Lee Musso
Original Assignee
Glaxo Group Ltd
Jessica E Matthews
David Lee Musso
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924275.2A external-priority patent/GB9924275D0/en
Priority claimed from GB0001861A external-priority patent/GB0001861D0/en
Application filed by Glaxo Group Ltd, Jessica E Matthews, David Lee Musso filed Critical Glaxo Group Ltd
Priority to AU77501/00A priority Critical patent/AU7750100A/en
Priority to JP2001529431A priority patent/JP2003511410A/ja
Priority to EP00967281A priority patent/EP1220673A2/fr
Publication of WO2001026641A2 publication Critical patent/WO2001026641A2/fr
Publication of WO2001026641A3 publication Critical patent/WO2001026641A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

L'invention concerne une méthode destinée au traitement de l'obésité, consistant à administrer à un animal nécessitant ce traitement, un composé représenté par la formule générale (I), ou un sel pharmaceutiquement acceptable de celui-ci ou un solvate pharmaceutiquement acceptable de celui-ci. L'invention concerne également des méthodes destinées à supprimer l'appétit, entraînant une perte de poids, prévenant la prise de poids, affectant de préférence les compositions adipeuses, inhibant l'état de manque de nourriture et permettant de maintenir la perte de poids.
PCT/US2000/027252 1999-10-13 2000-10-03 Methode destinee au traitement de l'obesite WO2001026641A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU77501/00A AU7750100A (en) 1999-10-13 2000-10-03 Method for the treatment of obesity
JP2001529431A JP2003511410A (ja) 1999-10-13 2000-10-03 肥満症の治療のためのモルホリノール誘導体
EP00967281A EP1220673A2 (fr) 1999-10-13 2000-10-03 Methode destinee au traitement de l'obesite

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9924275.2A GB9924275D0 (en) 1999-10-13 1999-10-13 Method for the treatment of obesity
GB9924275.2 1999-10-13
GB0001861.4 2000-01-28
GB0001861A GB0001861D0 (en) 2000-01-28 2000-01-28 Method for the treatment of obesity

Publications (2)

Publication Number Publication Date
WO2001026641A2 WO2001026641A2 (fr) 2001-04-19
WO2001026641A3 true WO2001026641A3 (fr) 2002-01-10

Family

ID=26243494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027252 WO2001026641A2 (fr) 1999-10-13 2000-10-03 Methode destinee au traitement de l'obesite

Country Status (6)

Country Link
EP (1) EP1220673A2 (fr)
JP (1) JP2003511410A (fr)
AR (1) AR026022A1 (fr)
AU (1) AU7750100A (fr)
PE (1) PE20010744A1 (fr)
WO (1) WO2001026641A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001165A (es) 2001-08-08 2004-05-20 R Orton Kevin Aparato y metodo para una reduccion de peso electricamente conductiva.
EP2301537A1 (fr) * 2002-05-17 2011-03-30 Duke University Zonisamide pour le traitement de l'obésité
SI2316456T1 (sl) 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
MX2010006220A (es) * 2007-12-05 2010-08-17 Astrazeneca Ab Derivados de morfolina como agentes antiobesidad.
CA2725930A1 (fr) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Procedes pour traiter des pathologies des graisses viscerales
MX2010013353A (es) * 2008-06-04 2010-12-21 Astrazeneca Ab Nuevos compuestos vii.
DK3730132T3 (da) 2012-06-06 2022-08-08 Nalpropion Pharmaceuticals Llc Sammensætning til anvendelse ved en fremgangsmåde til behandling af overvægt og obesitas hos patienter med høj kardiovaskulær risiko

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0426416A1 (fr) * 1989-10-31 1991-05-08 The Wellcome Foundation Limited Nouveaux composés de morpholinole, leur préparation et leur application
WO1998047513A1 (fr) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Utilisation des antagonistes du recepteur de nk-1 dans le traitement des troubles alimentaires
WO1999025355A1 (fr) * 1997-11-14 1999-05-27 Glaxo Group Ltd. Procede de traitement de l'accoutumance a des produits contenant de la nicotine
WO1999037305A1 (fr) * 1998-01-21 1999-07-29 Glaxo Group Limited Morpholinol pharmaceutiquement actif
WO2000018406A1 (fr) * 1998-09-28 2000-04-06 Glaxo Group Limited Formes posologiques a administration par voie orale contenant le compose (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol et une quantite stabilisante efficace d'acide alginique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0426416A1 (fr) * 1989-10-31 1991-05-08 The Wellcome Foundation Limited Nouveaux composés de morpholinole, leur préparation et leur application
WO1998047513A1 (fr) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Utilisation des antagonistes du recepteur de nk-1 dans le traitement des troubles alimentaires
WO1999025355A1 (fr) * 1997-11-14 1999-05-27 Glaxo Group Ltd. Procede de traitement de l'accoutumance a des produits contenant de la nicotine
WO1999037305A1 (fr) * 1998-01-21 1999-07-29 Glaxo Group Limited Morpholinol pharmaceutiquement actif
WO2000018406A1 (fr) * 1998-09-28 2000-04-06 Glaxo Group Limited Formes posologiques a administration par voie orale contenant le compose (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol et une quantite stabilisante efficace d'acide alginique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KELLEY JAMES L ET AL: "-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: A novel antidepressant agent and selective inhibitor of norepinephrine uptake.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 2, 1996, pages 347 - 349, XP002164358, ISSN: 0022-2623 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9107837B2 (en) 2006-06-05 2015-08-18 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression

Also Published As

Publication number Publication date
AU7750100A (en) 2001-04-23
EP1220673A2 (fr) 2002-07-10
JP2003511410A (ja) 2003-03-25
WO2001026641A2 (fr) 2001-04-19
PE20010744A1 (es) 2001-07-23
AR026022A1 (es) 2002-12-26

Similar Documents

Publication Publication Date Title
WO2001026641A3 (fr) Methode destinee au traitement de l'obesite
JP2001503780A5 (fr)
TR200102646T2 (tr) Yeme bozukluklarının tedavi edilmesi.
IL143978A0 (en) Colchinol derivatives as vascular damaging agents
WO2004029031A3 (fr) Agents therapeutiques utiles dans le traitement de la douleur
WO2004012700A3 (fr) Nouvelle forme galenique
WO2003011881A3 (fr) Derives de sucre d'hydromorphone, dihydromorphine et dihydroisomorphine, leurs compositions et leur utilisation dans le traitement ou la prevention de la douleur
WO2000068198A3 (fr) Derives de pyridine heterosubstitues utilises comme inhibiteurs de pde 4
EP1733734A3 (fr) Phosphatase alcaline placentaire destinée à équilibrer le diabete
AU2002239830A1 (en) Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof
WO2001012169A3 (fr) Traitement anticancereux
NZ332965A (en) 4- or 7-benzylamino or benzylmethyl substituted 2-methyl-benzimidazole derivatives
WO2000064874A3 (fr) DERIVES DE PYRIDINE HETEROSUBSTITUES INHIBITEURS DE $i(PDE 4)
CA2389032A1 (fr) Agents de prevention ou de traitement de maladies inflammatoires de l'intestin
EP1152002A4 (fr) Derives de pyrrole et inhibiteurs de la mort cellulaire
RU94044357A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования увеличения веса, индуцирования снижения веса или ингибирования аппетита
WO1998006265A3 (fr) Traitement d'infections fongiques a l'aide d'une combinaison d'un compose antifongique et d'un compose n-alkyle heterocyclique
CA2386685A1 (fr) Utilisation de derives de pleuromutiline pour le traitement transdermique de maladies bacteriennes
HK1044951A1 (en) Novel a-500359 derivatives
ZA200105886B (en) Agent of treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient.
CA2443235A1 (fr) Compositions pharmaceutiques comprenant de l'ascomycine
ZA928876B (en) Thiazole derivatives.
EP1238652A4 (fr) Compositions de peeling
CA2320627A1 (fr) Medicaments contre les troubles cardio-diastoliques
MY122570A (en) Benzamide derivatives and drugs containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000967281

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 529431

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10110624

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000967281

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000967281

Country of ref document: EP